Concord Biotech Ltd Share Price

Overview

Concord Biotech Ltd share price is currently ₹1,520.52, down by - ₹5.27 (0.35%) from its previous closing price of ₹1,525.79. The share price has gained 21.68% over the past month and declined -5.8% over the past year. The stock's 52-week low and high are ₹973.46 and ₹1,722.71, respectively. Concord Biotech Ltd has a market capitalisation of ₹ 16,440.00 Cr. The share price was last updated on 25 Aug 2026, 03:57 PM IST.

Concord Biotech Ltd

CONCORDBIO

₹0.00

- ₹5.27

0.35%

Healthcare

₹0.00(%)1D

Updated: 25 Aug 2026, 03:57:34 pm IST

Market Data

Open Price

₹1,522.93

Prev. Close

₹1,525.79

₹1,495.26

Day Low

₹1,532.77

Day High

₹973.46

52 Week Low

₹1,722.71

52 Week High

HealthcarePharmaceuticals & Drugs

CategoryMid Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

57.77

Sector PE

42.03

PB Ratio

7.89

Sector PB

5.83

EPS

26.32

Dividend Yield

0.74

Today's Volume

53.566 K

5 Day Avg. Volume

127.486 K

PEG Ratio

-1.94

Market Cap.

₹ 16,440.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 755% at ₹7.55/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 1070% at ₹10.7/Share	03-Sep-2025	03-Sep-2025

Mutual Fund Ownership

Mutual Fund Holder	Jun 26 Shares held	Jul 26 Shares held
DSP Small Cap Fund - Regular Plan - Growth	13.32 Lac	13.32 Lac no change
SBI Healthcare Opportunities Fund - Regular Plan - IDCW	7.20 Lac	7.20 Lac no change
Edelweiss Small Cap Fund - Regular Plan - Growth	5.65 Lac	5.65 Lac no change
DSP Healthcare Fund - Regular Plan - Growth	4.97 Lac	4.97 Lac no change
Quant Healthcare Fund - Regular Plan - Growth	2.70 Lac	2.70 Lac no change

Show all holdings

About Concord Biotech Ltd 👋

Concord Biotech Limited is an India-based research and development-driven biopharmaceutical company focused on manufacturing fermentation-based active pharmaceutical ingredients (APIs) and formulations. The Company is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its product portfolio encompasses both biopharmaceutical APIs and formulations across various therapeutic areas, including immunosuppressants, oncology, anti-infectives, nephrology, and critical care. Its API products include Immunosuppressant, Oncology Drugs, Anti-bacterial, and others. Its Immunosuppressant include Tacrolimus, Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, and Voclosporin. Its Oncology Drugs include Temsirolimus, Everolimus, Romidepsin, Mitomycin, Dactinomycin, Midostaurin, and Doxorubicin. Its Anti-bacterial include Mupirocin, Mupirocin Calcium, Teicoplanin, and others.